General News
CooperVision marks Myopia Awareness Week with newly published study
CooperVision marks Myopia Awareness Week with newly published MiSight® 1 day study in peer-reviewed journal
Seven-year study confirms lasting myopia control with MiSight® 1 day contact lenses post-treatment
In celebration of Myopia Awareness Week 2025 (19th – 25th May) CooperVision is delighted to share a new, peer-reviewed paper, published in Optometry and Vision Science, which confirms that myopia control gains with CooperVision’s MiSight® 1 day* dual-focus soft contact lenses are sustained after treatment, with post-treatment eye growth aligning with that of untreated, age-matched populations.1
The seven-year study followed subjects who had completed the six-year MiSight® 1 day clinical trial—both the cohort who wore MiSight® 1 day for all six years and the cohort who switched from the single vision to the MiSight® 1 day lens for the final three years—for an additional year following treatment cessation. The results showed that children retained the benefits of myopia control without experiencing accelerated myopia progression post-treatment, further strengthening support for treating children with MiSight® 1 day.
By utilising virtual control groups based on myopic children of the same age as those observed in year seven of this study, the new paper also provides the most robust validation to date of this model for assessing long-term myopia control outcomes. Investigators applied the model to the study’s preliminary outcomes data, first shared in 2021, and subsequently found their initial conclusions to be highly accurate.
Paul Chamberlain, Senior Director of Research Programmes at CooperVision and the paper’s lead author said: “Eye care professionals (ECPs) have embraced the importance of myopia control in children, and we are starting to see this reflected in prescribing behaviour around the world.”
“To turn the tide on childhood myopia, ECPs must be confident in an intervention that not only slows progression†2 but makes long-term treatment worthwhile. MiSight® 1 day clearly demonstrates these benefits, allowing ECPs to prescribe with confidence for both immediate and lasting impact.”
This latest study is now accessible via Open Access: Eye Growth and Myopia Progression Following Cessation of Myopia Control Therapy with a Dual-Focus Soft Contact Lens1 (Chamberlain P et al.) joining the widely-cited three-year and six-year results,2,3 all of which are published in Optometry and Vision Science, the journal of the American Academy of Optometry.
For more information on MiSight® 1 day, speak to your CooperVision Business Development Manager or visit www.coopervision.co.uk
* Regulatory indications of and access to interventions for slowing myopia progression vary by country. CooperVision does not endorse off-label prescribing.
† Compared to single vision lens, no clinically meaningful change in refractive error (-0.25D or less from baseline). Fitted at 8-12 years of age.
References
1 Chamberlain, P, et al. Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens. Optom and Vis Sci. 2025 Mar 25; ():10.1097/OPX.0000000000002244.
2 Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-572.
3 Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-yearMulticenter Clinical Trial. Optom Vis Sci. 2022 Mar 1;99(3):204-212.
